These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2217473)

  • 1. Second line treatment of hormone refractory prostatic cancer patients.
    Collste LG
    Prog Clin Biol Res; 1990; 357():29-37. PubMed ID: 2217473
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hormonal, radiation and combined therapy of locally advanced prostatic cancer (T3NXM0)].
    Pavlov AS; Loran OB; Simakina EP; Tomkevich BA; Repina AG; Gribova RG
    Urologiia; 2005; (4):24-6. PubMed ID: 16158741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The late results of the combined hormonal chemoradiation treatment of prostatic cancer].
    Sviridova TV; Mardynskiĭ IuS; Tsodikova LB; Rozhkov OV
    Urol Nefrol (Mosk); 1996; (1):31-4. PubMed ID: 8659040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New hormonal treatments of metastatic prostatic cancer. Review of the literature].
    Dubost JJ; Sauvezie B; Ristori JM; Thevenet JP; Rampon S
    Rev Rhum Mal Osteoartic; 1985 Oct; 52(10):577-85. PubMed ID: 3909364
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of chemotherapy in the treatment of prostatic carcinoma.
    Tonato M; Bracarda S
    Rays; 1993; 18(1):87-93. PubMed ID: 8356244
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of advanced prostate cancer].
    Okada K; Akino H; Suzuki Y; Miwa Y; Saikawa S; Fujita T; Aoki Y; Iwaoka K
    Hinyokika Kiyo; 1994 Oct; 40(10):945-50. PubMed ID: 7992712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone chemotherapy for newly diagnosed patients with metastatic prostate cancer.
    Kubota Y; Nakada T; Suzuki Y; Iizima Y; Adachi Y; Hashimoto T
    Int Urol Nephrol; 1993; 25(5):469-74. PubMed ID: 8270375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incorrect about hormone treatment in prostatic cancer].
    Fosså SD; Egey A; Haukaas SA; Angelsen A; Klepp O; Berge V; Axcrona K; Lilleby W
    Tidsskr Nor Laegeforen; 2009 Feb; 129(5):429. PubMed ID: 19247406
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prostatic adenocarcinoma. I. History of its treatment and study of its prognostic factors. Review of the literature].
    Valls Fontanals A; Panadés Nigorra G; Ballester Moll T
    Actas Urol Esp; 1985; 9(2):109-14. PubMed ID: 3893052
    [No Abstract]   [Full Text] [Related]  

  • 10. The management of end-stage carcinoma of the prostate: philosophy and fact.
    Robinson MR
    Prog Clin Biol Res; 1990; 357():39-44. PubMed ID: 2217476
    [No Abstract]   [Full Text] [Related]  

  • 11. Atrasentan demonstrates survival benefit in hormone-refractory prostate cancer.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):245. PubMed ID: 12113043
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of newly diagnosed metastatic carcinoma of the prostate.
    Elder JS; Catalona WJ
    Urol Clin North Am; 1984 May; 11(2):283-95. PubMed ID: 6428022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic and therapeutic aspects of prostatic carcinoma].
    Studer UE
    Schweiz Rundsch Med Prax; 1988 May; 77(20):545-50. PubMed ID: 3291053
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapeutic problems in hormone-dependent cancer].
    Zimel H
    Stud Cercet Endocrinol; 1969; 20(2):111-25. PubMed ID: 4898947
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy?
    Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Shapiro A
    BJU Int; 2009 Apr; 103(7):905-8. PubMed ID: 19021623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advanced prostatic carcinoma--which hormone therapy when?].
    Studer UE
    Urologe A; 1995 Sep; 34(5):361-6. PubMed ID: 7483151
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy of advanced prostatic cancer].
    Sagaster P; Flamm J
    Wien Med Wochenschr; 1988 Apr; 138(8):169-73. PubMed ID: 3043920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current strategies in the treatment of metastatic hormone-refractory prostate cancer.
    Ghosn M; Kattan J; Younes F
    Tunis Med; 2005 Dec; 83 Suppl 12():74. PubMed ID: 16430073
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment for hormone-refractory or relapsing prostatic cancer].
    Hirao Y; Ozono S; Okajima E
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer: metastatic.
    Michaelson D; Talcott J; Smith M
    Clin Evid; 2002 Jun; (7):804-11. PubMed ID: 12230706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.